Malignant hyperthermia is a life-threatening disorder of skeletal muscle which was first recognised in the 1960s when Denborough described the deaths of more than ten family members 1 . During those early times, mortality with this disorder was nearly 80% 2 . Harrison demonstrated in 1975 that malignant hyperthermia in pigs could be controlled by intravenous dantrolene 3 , and today, with better education, prompt recognition of the hypermetabolic state and use of intravenous dantrolene, the mortality rate is less than 5%.
The first signs of malignant hyperthermia may be an unexpected rise in ETCO 2 or unexplained tachycardia. Core temperature can increase as much as 1°C every five minutes 4 . The reason for these life-threatening changes is an extensive release of calcium from the sarcoplasmic reticulum in the skeletal muscle.
The risk of a fatality is high if the syndrome is not recognised and treated promptly. Discontinuation of triggering agents, cooling and the rapid administration of dantrolene are the cornerstones of effective management.
Dantrolene sodium was initially synthesised as a possible antibiotic and was shown to cause muscle weakness in animals. Further studies identified that it inhibited the intracellular calcium release from the sarcoplasmic reticulum 5, 6 .
In 1982 Kolb et al reviewed the treatment of malignant hyperthermia in 65 hospitals in North America 7 . They showed that early treatment with dantrolene reversed the physiologic, metabolic and biochemical changes associated with the crisis of malignant hyperthermia. After this review dantrolene became the main cornerstone in the treatment of malignant hyperthermia.
The only intravenous dantrolene formulation is Dantrium ® (JHP Pharmaceuticals, NJ, USA). It contains 20 mg of dantrolene, 3 g of mannitol and SUMMARY Dantrolene is known to have a low solubility in water. Studies have demonstrated that it dissolves more rapidly in warm water. However, the overall benefit of warming has not been measured. This study evaluated the overall time benefit of warming.
The first step was to measure how long it took to warm the 10 ml plastic ampoules of sterile water from ambient temperature (20°C) to 45°C. We found that when immersed in a water bath held at 45°C, this required a minimum of seven minutes. Therefore the ampoules used for the study were kept immersed in a water bath held at 45°C for at least 10 minutes.
It took an average of 82.6 seconds to draw 60 ml (six ampoules) of water into a 60 ml syringe. Squirting the water into the dantrolene vial and mixing until dissolved took 102.8 seconds (SD 8.3) for the warmed water and 129.0 seconds (SD 14.6) for the ambient temperature water (P=0.009). Redrawing the dantrolene solution into the syringe took an average of 32 seconds for the warmed water and 35.2 seconds for the ambient temperature water. After the redrawing phase the average temperature of the warmed solution was 32.2°C. The average total preparation time for the warmed solution was 217.4 seconds (SD 20.0) and for the ambient temperature preparation was 243.0 seconds (SD 11.7) (P=0.038).
Thus the time difference in preparation was about 256 seconds, which is the time that could be saved in preparing the standard dose of 10 vials of dantrolene using water at 45°C. However, as it required about seven minutes to initially warm the sterile ampoules, there would be a net increase, not decrease in the time required. These findings indicate that warming is of no benefit in speeding dantrolene preparation.
Key Words: dantrolene preparation, malignant hyperthermia sodium hydroxide. Product guidelines recommend an initial 1 mg/kg intravenous dose but 2.5 mg/kg is recommended by Malignant Hyperthermia Australia and New Zealand. The initial dose should be repeated until symptoms and signs are controlled. This may require up to 10 mg/kg. However, in some patients larger doses may be necessary. For the average 80 kg adult, this means an initial dose of 200 mg, which requires 10 vials of the powder to be prepared.
Each vial of Dantrium must be reconstituted by adding 60 ml of sterile water and shaken until the solution is clear. As dantrolene is poorly soluble in water, some time is required to reconstitute the 10 or more vials of dantrolene needed for the initial therapy 4, 8 . Because the clinical preparation is timeconsuming, some studies have searched for ways to speed up dantrolene into solution. These studies have demonstrated that mixing dantrolene with warm water rather than water at ambient temperature speeds its reconstitution 9, 10 . However, warming the sterile water itself takes time before it is ready to dissolve the dantrolene and this is only one step in the process of administration.
This current study aimed to investigate both the time involved in warming and the time benefit of warming dantrolene solution for administration, to determine whether there was an overall time-saving.
MATERIALS AND METHODS
Three experiments were performed in the simulation operating theatre of the Royal Adelaide Hospital. The first was to measure how long it took to warm the sterile ampoules of water to 45°C from the ambient temperature (20°C). The second was to measure the speed of preparing the dantrolene in an ambient temperature of 20°C after the ampoule water had been warmed initially to 45°C. The third trial was performed in the same manner, but without the ampoules being warmed (ambient temperature 20°C).
The following materials were used: Dantrium powder for injection, 10 ml plastic ampoules of sterile water as the diluents, jug with water warmed to 45°C, temperature measurements with calibrated electronic temperature probes and a stopwatch to measure the time.
Experiment 1
We warmed the water in the jug to 45°C and put 10 ampoules of sterile water in the water. No further warming was applied to the jug, which was allowed to stand at ambient (20°C) temperature. The water temperature in the jug was measured continuously with an electronic thermometer. Every minute, one of the water ampoules was removed from the jug, opened and the temperature immediately measured.
Experiment 2
Ampoules of sterile water were placed into a jug, which contained water at 45°C. The temperature in the jug was measured continuously with an electronic thermometer but unlike experiment 1, small amounts of hot water were added as necessary to keep the water temperature of the jug stable at 45°C.
The ampoules were in the jug for at least 10 minutes so that the sterile water in the ampoules reached equilibrium (45°C), as shown in experiment 1 (see Results). We drew up six 10 ml ampoules of water into a 60 ml syringe. The drawing up time and the temperature of the water in the syringe were measured (Table 1, Aspiration 1). In a second step we injected the water into a vial of dantrolene and shook it until the solution was clear. The time taken by the process was also measured ( Table 1 , Inject and dissolve). Finally, we redrew the dissolved dantrolene back into the syringe (Table 1 , Aspiration 2) and measured the end temperature and total time of the whole process ( Table 1 , Total). During all of this preparation, the ambient temperature was 20°C.
Experiment 3
In experiment 3, the same steps as in experiment 2 were performed. However, the water in the ampoules was not warmed, but remained at ambient (20°C) temperature. The time of each step was measured as in experiment 2. The individual experiment results and averages (SD) are shown in Table 2 . 
ANALYSIS
The groups were analysed statistically with unpaired two-sided Student's t-tests.
RESULTS

Experiment 1
The change in temperature for both the jug and the water ampoules are shown in Figure 1 . The ampoule temperature initially rose rapidly to about 38°C in the first two minutes, but did not achieve equilibrium until about seven minutes. Over seven minutes, the time to achieve equilibrium, the temperature of the water in the jug fell about 6°C degrees.
Experiment 2
The results of the five trials are given in Table 1 . The average (SD) time for drawing up the sterile water from the six ampoules was 82.6±7.5 seconds and by then the temperature in the 60 ml syringe of the water was 38.06±0.44°C. The average (SD) time to dissolve the dantrolene after the warm water was added was 102.8±8.3 seconds. It took a further 32.0±4.2 seconds to draw the dantrolene solution back into the 60 ml syringe, by which time the temperature had fallen further to 32.2±0.4°C at the moment of administration. Thus the average total time for drawing up the sterile warm water, dissolving the dantrolene and re-drawing the solution into the 60 ml syringe was 217.4±20.0 seconds.
Experiment 3
The drawing up time for the sterile water was similar to experiment 2 at a mean SD 78.6±6.0 seconds, T=0.93, P=0.38. The average (SD) time of dissolving the dantrolene with water ampoules at room temperature was slower at 129±14.6 seconds. This was statistically significantly slower than the warmed solution (Student's t-test 3.42, P=0.009). The average (SD) on total preparation time was also slower at 243±11.6 seconds ( 
DISCUSSION
Warming the water in ampoules must be done carefully. If the water is too hot it could harm the patient, but cool water means slower preparation. We selected 45°C as the initial temperature to remove the risk of overheating, but to achieve the fastest solubilisation.
With this warming, the rate of dissolving dantrolene was speeded up by an average of 25.6 seconds per dantrolene vial. However this measurement does not take into account the seven minutes of warming the ampoules, and that is assuming that all the necessary equipment is immediately available.
As in other studies [8] [9] [10] , this trial found that a warm diluent decreases the dissolving time of dantrolene. In contrast to previous studies which have used lower temperatures, the sterile water in this trial was The time needed to dissolve dantrolene with sterile water at room temperatures. As in experiment 2 the single working steps and the total time were measured. Temperature was not measured. warmed to 45°C. At this temperature the dissolving was about 20% faster. Withdrawing the warmed diluents back into a syringe was associated with a decrease in the temperature of the solution to about 32°C. A similar cooling effect was also noted by Baker et al in their studies 11 . A temperature at injection of 32.2°C will not harm tissues or blood vessels. It is recommended that in a crisis an initial bolus dose of 2.5 mg/kg should be administered as soon as possible, followed by subsequent 2.5 mg/kg doses every five minutes up to 10 mg/kg until signs of malignant hyperthermia are ceased. Even though the onset time of malignant hyperthermia varies between 10 minutes and more than four hours 12 , rapid preparation of the dantrolene still is essential as patients may progress in only 20 minutes to severe acidosis, shock and ventricular fibrillation 13 .
In this trial, the time saved in dissolving dantrolene with warmed water was about 25.6 seconds per dantrolene vial. Considering this is only one step in the process, one might question the value of this gain, particularly as extra time will be required to warm the water ampoules.
As shown in experiment 1, it takes about seven minutes for the water ampoules to warm up to the desired temperature, assuming that all the necessary equipment is already available.
It seems unlikely that in an emergency setting, any time at all could be saved. On the contrary, the chances are high that if warming is implemented, time may be lost. Moreover, there may be further time lost in setting up the intravenous fluid warmer to fill the dantrolene vials, as suggested in one study 9 .
For an 80 kg patient, one would need to dissolve 10 vials for a 2.5 mg/kg initial dose. In this study, the time to prepare this dose would take an average time of 40.5 minutes with diluents at room temperatures and 36.5 minutes with diluents heated up to 45°C. As shown in experiment 1, the time to warm up the ampoules to the desired temperature takes approximately seven minutes. Therefore, no time is saved with warmed diluents if the ampoules must be warmed.
Some other suggestions have been made that the dantrolene vial should be heated either by immersing it into hotter water or autoclaving 4 . These procedures could create solutions that are too hot and therefore could cause burns or venous thrombosis 14, 15 .
Other recommendations have described the use of an intravenous fluid warmer to fill the dantrolene vials with the help of a three-way stopcock attached to the dantrolene vial 8 . Even though this seems to be a sure way to heat the sterile water, one might assume that setting up such a system in the stress of an anaesthetic emergency might well cost more time than just dissolving the dantrolene at ambient temperatures.
In this study, the temperature of the warmed diluents dropped during the preparation to an average of 32°C. Therefore it might be possible to dissolve dantrolene faster with higher starting temperatures to speed up the process and save more time while still being safe for the patient. With an increase in temperature, the stability of the solution may be reduced. The current product information advises that once reconstituted, the solution should be used within six hours. Storage is specified as 25°C, assuming a reaction Q10 rate of about 2.2 which is usual for organic compounds: increasing the solution temperature from 25°C to 35°C would therefore reduce the stability time to 2.7 hours, or further to 1.2 hours if kept at 45°C.
A more water-soluble preparation of dantrolene is currently under investigation 16 .
From this study it appears that there is no time advantage in heating the sterile ampoules of water to dissolve the dantrolene and a risk that the added complexity of the task may indeed slow rather than speed the preparation.
